Literature DB >> 20819714

[O-GlcNAc glycosylation and regulation of cell signaling].

Tarik Issad1.   

Abstract

O-GlcNAcylation corresponds to the addition of N-acetylglucosamine on serine and threonine residues of cytosolic and nuclear proteins. O-GlcNAcylation is a dynamic post-translational modification, analogous to phosphorylation, that regulates the stability, the activity or the sub-cellular localisation of proteins. This reversible modification depends on the availability of glucose and therefore constitutes a powerful means by which cellular activities are regulated according to the nutritional environment of the cell. O-GlcNAcylation has been implicated in important human pathologies including Alzheimer disease and type-2 diabetes. Only two enzymes, OGT and O-GlcNAcase, control the O-GlcNAcylation level on proteins, and thereby regulate signaling pathways. Several lines of evidence indicate that OGT attenuates insulin signal by O-GlcNAcylation of proteins involved in proximal and distal steps in the signaling pathway. This negative feedback may be exacerbated when cells are exposed to elevated glucose concentrations as observed in diabetic patients, and could thereby contribute to insulin resistance and worsening of hyperglycaemia. double dagger.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20819714     DOI: 10.1051/medsci/2010268-9753

Source DB:  PubMed          Journal:  Med Sci (Paris)        ISSN: 0767-0974            Impact factor:   0.818


  2 in total

Review 1.  O-GlcNAcylation: The Underestimated Emerging Regulators of Skeletal Muscle Physiology.

Authors:  Yang Liu; Ya-Jie Hu; Wen-Xuan Fan; Xin Quan; Bin Xu; Shi-Ze Li
Journal:  Cells       Date:  2022-05-30       Impact factor: 7.666

2.  Discovery and confirmation of O-GlcNAcylated proteins in rat liver mitochondria by combination of mass spectrometry and immunological methods.

Authors:  Weiqian Cao; Jing Cao; Jiangming Huang; Jun Yao; Guoquan Yan; Haoqi Xu; Pengyuan Yang
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.